1-4 of 4
Veronique Blanc
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner

Janet K. Peper-Gabriel, Marina Pavlidou, Lucia Pattarini, Aizea Morales-Kastresana, Thomas J. Jaquin, Catherine Gallou, Eva-Maria Hansbauer, Marleen Richter, Helene Lelievre, Alix Scholer-Dahirel, Birgit Bossenmaier, Celine Sancerne, Matthieu Riviere, Maximilien Grandclaudon, Markus Zettl, Rachida S. Bel Aiba, Christine Rothe, Veronique Blanc, Shane A. Olwill
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3387–3399.
https://doi.org/10.1158/1078-0432.CCR-21-2762
Published: 02 August 2022
View article titled, The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner
Open the PDF for The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner in another window
Includes: Supplementary data
Journal Articles

Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors

Stéphanie Decary, Pierre-François Berne, Céline Nicolazzi, Anne-Marie Lefebvre, Tarik Dabdoubi, Béatrice Cameron, Pierrick Rival, Catherine Devaud, Catherine Prades, Hervé Bouchard, Alhassan Cassé, Christophe Henry, Céline Amara, Claire Brillac, Paul Ferrari, Laetitia Maçon, Eric Lacoste, Cecile Combeau, Eric Beys, Souad Naimi, Carlos García-Echeverría, Jean-François Mayaux, Véronique Blanc
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (24): 6589–6599.
https://doi.org/10.1158/1078-0432.CCR-19-4051
Published: 15 December 2020
View article titled, Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors
Open the PDF for Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors in another window
Includes: Supplementary data
Journal Articles

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

Jutta Deckert, Marie-Cécile Wetzel, Laura M. Bartle, Anna Skaletskaya, Victor S. Goldmacher, François Vallée, Qing Zhou-Liu, Paul Ferrari, Stéphanie Pouzieux, Charlotte Lahoute, Charles Dumontet, Adriana Plesa, Marielle Chiron, Pascale Lejeune, Thomas Chittenden, Peter U. Park, Véronique Blanc
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4574–4583.
https://doi.org/10.1158/1078-0432.CCR-14-0695
Published: 01 September 2014
View article titled, SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38<sup>+</sup> Hematologic Malignancies
Open the PDF for SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38<sup>+</sup> Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies

Veronique Blanc, Anne Bousseau, Anne Caron, Chantal Carrez, Robert J. Lutz, John M. Lambert
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (20): 6448–6458.
https://doi.org/10.1158/1078-0432.CCR-11-0485
Published: 14 October 2011
View article titled, SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
Open the PDF for SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies in another window